Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, inrats

Pharmazie

Volumn 68, Issue 11, 2013, Pages 882-888

  Choi, J S ^a,a   Choi, Dong Hyun ^a  

^a Chosun University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; LICOCHALCONE A; LOSARTAN; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SMALL INTESTINE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AREA UNDER CURVE; CHALCONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FLUORESCENT DYES; HALF-LIFE; IMIDAZOLES; LOSARTAN; MALE; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; TETRAZOLES;

EID: 84889005475     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2013.3600     Document Type: Article

References (36)

1. Benet LZ, Cummins CL, Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4: 393-398.
2. Chen M, Theander TG, Christensen SB, Hviid L, Zhai L, Kharazmi A (1994) Licochalcone, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob Agents Chemother 38: 1470-1475.
3. Cho YA, Choi DH, Choi JS (2009) Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. J Pharm Pharmacol 61: 825-829.
4. Choi DH, Li C, Choi JS (2010) Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol 62: 908-914.
5. Cho YA, Lee W, Choi JS (2012) Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-gp inhibition by curcumin. Pharmazie 67: 124-130.
6. Chung JH, Choi DH, Choi JS (2009) Effect of epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos 30: 90-93.
7. Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248: 188-190.
8. Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300: 1036-1045.
9. De Vincenzo R, Ferlini C, Distefano M, Gaggini C, Riva A, Bombardelli E, Morazzoni P, Valenti P, Belluti F, Ranelletti FO, Mancuso S, Scambia G (2000) In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother Pharmacol 46: 305-312.
10. Diez J (2006) Review of the molecular pharmacology of losartan and its possible relevance to stroke prevention in patients with hypertension. Clin Ther 28: 832-848.
11. Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z, Wu JM (2004) Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 322: 263-270.
12. Han CY, Cho KB, Choi HS, Han HK, Kang KW (2008) Role of FoxO1 activation in MDR1expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29: 1837-1844.
13. Haraguchi H, Ishikawa H, Mizutani K, Tamaru Y, Kinoshita T (1998) Antioxidative and superoxide scavenging activities of retrochalcones in glycyrrhiza inflate. Bioorg Med Chem 6: 339-347.
14. Inagami T, Iwai N, Sasaki K, Yamamo Y, Bardhan S, Chaki S, Guo DF, Furuta H (1992) Cloning, expression and regulation of angiotensin II receptors. J Hypertens 8: 713-716.
15. Kaukonen KM, Olkkola KT, Neuvonen PJ (1998) Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53: 445-449.
16. Kelly PA,Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24: 321-328.
17. Kim YH, Shin EK, Kim DH, Lee HH, Park JH, Kim JK (2010) Antiangiogenic effect of licochalcone A. Biochem Pharmacol 80: 1152-1159.
18. Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G (2005) Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull 28: 2274-2278.
19. Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K (2008) The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 23: 115-119.
20. Krieter PA, Colletti AE, Miller RR, Stearns RA (1995) Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. J Pharmacol Exp Ther 273: 816-822.
21. Kwon HS, Park JH, Kim DH, Kim YH, Park JH, Shin HK, Kim JK (2008) Licochalcone A isolated from licorice suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice. J Mol Med 86: 1287-1295.
22. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58: 641-649.
23. McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S, Goldberg MR (1999) Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 65: 348-352.
24. McIntyre M, Caffe SE, Michalak RA, Reid JL (1997) Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 74: 181-194.
25. Meadowcroft AM, Williamson KM, Patterson JH, Hinderliter AL, Pieper JA (1999) The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol 39: 418-424.
26. Piao YJ, Choi JS (2008) Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J Pharm Pharmacol 60: 625-629.
27. Piao YJ, Choi JS (2008) Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res 31: 518-522.
28. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, Lambert G, DiPaola RS (2002) Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 20: 2653-2658.
29. Shibata S (1994) Anti-tumorigenic chalcones. Stem Cells 12: 44-52.
30. Soldner A, Benet LZ, Mutschler E, Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol 129: 1235-1243.
31. Stearns RA, Chakravarty PK, Chen R, Chiu SH (1995) Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 23: 207-215.
32. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt D (2004) Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56: 1039-1044.
33. Yun CH, Lee HS, Lee H, Rho JK, Jeong HG, Guengerich FP (1995) Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 23: 285-289.
34. Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E (2001) Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 23: 369-373.
35. Zarghi A, Foroutan SM, Shafaati A, Khoddam A (2005) A rapid HPLC method for the determination of losartan in human plasma using a monolithic column. Arzneimittelforschung 55: 569-572.
36. Zhai L, Chen M, Blom J, Theander TG, Christensen SB, Kharazmi A (1999) The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 43: 793-803.